Novel Maintenance Combination in Advanced Ovarian Cancer
Ovarian Cancer
Related Content
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024Article
In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More